Skeletal Muscle Tissue Engineering is a multidisciplinary field focused on developing artificial skeletal muscle tissues for therapeutic applications, regenerative medicine, and studying muscle physiology in vitro. Researchers aim to create functional muscle constructs that mimic the structure and function of native skeletal muscle tissue. The process involves combining cells, biomaterial scaffolds, and signaling factors to encourage tissue formation. Cells used in skeletal muscle tissue engineering often include myoblasts, satellite cells, or pluripotent stem cells, which are cultured on biocompatible scaffolds that provide structural support and mimic the extracellular matrix of native muscle tissue. These scaffolds guide cell alignment and organization, crucial for the development of functional muscle fibers. Various techniques are employed to stimulate cell differentiation and maturation within engineered muscle tissues. Electrical and mechanical stimulation, along with biochemical cues, help promote the formation of contractile muscle fibers. Additionally, the incorporation of vascularization strategies is crucial to ensure nutrient and oxygen supply to the engineered tissue. The ultimate goal of skeletal muscle tissue engineering is to create viable muscle grafts that can be used for transplantation or repair in patients with muscle injuries, defects, or degenerative disorders. This technology holds promise for addressing conditions such as volumetric muscle loss or muscular dystrophy.
Title : AI-integrated high-throughput tissue-chip for space-based biomanufacturing applications
Kunal Mitra, Florida Tech, United States
Title : Will be updated soon...
Vasiliki E Kalodimou, European University-Cyprus Ltd, Cyprus
Title : Will be updated soon...
Nagy Habib, Imperial College London, United Kingdom
Title : Will be updated soon...
Alexander Seifalian, Nanotechnology & Regenerative Medicine Commercialisation Centre, United Kingdom
Title : Advanced 3D tissue models: Pioneering tools for investigating health and disease
Lucie Bacakova, Institute of Physiology of the Czech Academy of Sciences, Czech Republic
Title : Developing iPSC-derived 3D Outer Blood-Retinal Barrier Disease Models of Choroideremia for Gene Therapy Evaluation
Aradhana Kasimsetty, National Center for Advancing Translational Sciences (NCATS), National Institutes of Health (NIH), United States